Synthesis and Evaluation of Antimalarial Properties of Novel 4‐Aminoquinoline Hybrid Compounds

Pharmacophore hybridization has recently been employed in the search for antimalarial lead compounds. This approach chemically links two pharmacophores, each with their own antimalarial activity and ideally with different modes of action, into a single hybrid molecule with the goal to improve therapeutic properties. In this paper, we report the synthesis of novel 7‐chloro‐4‐aminoquinoline/primary sulfonamide hybrid compounds. The chlorinated 4‐aminoquinoline scaffold is the core structure of chloroquine, an established antimalarial drug, while the primary sulfonamide functional group has a proven track record of efficacy and safety in many clinically used drugs and was recently shown to exhibit some antimalarial activity. The activity of the hybrid compounds was determined against chloroquine‐sensitive (3D7) and chloroquine‐resistant (Dd2) Plasmodium falciparum strains. While the hybrid compounds had lower antimalarial activity when compared to chloroquine, they demonstrated a number of interesting structure–activity relationship (SAR) trends including the potential to overcome the resistance profile of chloroquine.

[1]  Vipan Kumar,et al.  Urea/oxalamide tethered β-lactam-7-chloroquinoline conjugates: synthesis and in vitro antimalarial evaluation. , 2014, European journal of medicinal chemistry.

[2]  Marie Lopez,et al.  Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment. , 2013, Bioorganic & medicinal chemistry letters.

[3]  U. Schepers,et al.  Amphiphilic peptoid transporters--synthesis and evaluation. , 2013, Organic & biomolecular chemistry.

[4]  Maria M. M. Santos,et al.  Squaric acid/4-aminoquinoline conjugates: novel potent antiplasmodial agents. , 2013, European journal of medicinal chemistry.

[5]  P. Ringwald,et al.  Artemisinin resistance is a clear and present danger. , 2013, Trends in parasitology.

[6]  Shabana I. Khan,et al.  4‐Aminoquinoline‐Triazine‐Based Hybrids with Improved In Vitro Antimalarial Activity Against CQ‐Sensitive and CQ‐Resistant Strains of Plasmodium falciparum , 2013, Chemical biology & drug design.

[7]  Vipan Kumar,et al.  Azide-alkyne cycloaddition en route to 1H-1,2,3-triazole-tethered 7-chloroquinoline-isatin chimeras: synthesis and antimalarial evaluation. , 2013, European journal of medicinal chemistry.

[8]  C. Supuran,et al.  Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. , 2013, Journal of medicinal chemistry.

[9]  N. A. Malmquist,et al.  Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum , 2012, Proceedings of the National Academy of Sciences.

[10]  B. Tekwani,et al.  Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity. , 2012, ACS medicinal chemistry letters.

[11]  C. Supuran,et al.  Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII. , 2012, Journal of medicinal chemistry.

[12]  G. McFadden,et al.  Antimalarial Activity of the Anticancer Histone Deacetylase Inhibitor SB939 , 2012, Antimicrobial Agents and Chemotherapy.

[13]  Alan D. Lopez,et al.  Global malaria mortality between 1980 and 2010: a systematic analysis , 2012, The Lancet.

[14]  C. Biot,et al.  The antimalarial ferroquine: from bench to clinic , 2011, Parasite.

[15]  Shabana I. Khan,et al.  Synthesis of 4‐aminoquinoline‐1,2,3‐triazole and 4‐aminoquinoline‐1,2,3‐triazole‐1,3,5‐triazine Hybrids as Potential Antimalarial Agents , 2011, Chemical biology & drug design.

[16]  C. Supuran Bacterial Carbonic Anhydrases as Drug Targets: Toward Novel Antibiotics? , 2011, Front. Pharmacol..

[17]  G. Klebe,et al.  Stereo- and regioselective azide/alkyne cycloadditions in carbonic anhydrase II via tethering, monitored by crystallography and mass spectrometry. , 2011, Chemistry.

[18]  B. K. Park,et al.  Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. , 2010, Angewandte Chemie.

[19]  N. Day,et al.  Artemisinin resistance: current status and scenarios for containment , 2010, Nature Reviews Microbiology.

[20]  J. Wood,et al.  SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer , 2010, Molecular Cancer Therapeutics.

[21]  A. Gómez-Barrio,et al.  Recent developments in the design and synthesis of hybrid molecules based on aminoquinoline ring and their antiplasmodial evaluation. , 2009, European journal of medicinal chemistry.

[22]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[23]  P. Olliaro,et al.  The Global Portfolio of New Antimalarial Medicines Under Development , 2009, Clinical pharmacology and therapeutics.

[24]  A. Janowsky,et al.  Discovery of dual function acridones as a new antimalarial chemotype , 2009, Nature.

[25]  B. Mordmüller,et al.  Selection of a trioxaquine as an antimalarial drug candidate , 2008, Proceedings of the National Academy of Sciences.

[26]  M. D. de Souza,et al.  Synthesis, Antimalarial Activity, and Intracellular Targets of MEFAS, a New Hybrid Compound Derived from Mefloquine and Artesunate , 2008, Antimicrobial Agents and Chemotherapy.

[27]  D. Prosperi,et al.  A Combinatorial Approach to 2,4,6‐Trisubstituted Triazines with Potent Antimalarial Activity: Combining Conventional Synthesis and Microwave‐Assistance , 2008, ChemMedChem.

[28]  B. Meunier,et al.  Hybrid molecules with a dual mode of action: dream or reality? , 2008, Accounts of chemical research.

[29]  Giovanni Sorba,et al.  Click chemistry reactions in medicinal chemistry: Applications of the 1,3‐dipolar cycloaddition between azides and alkynes , 2008, Medicinal research reviews.

[30]  Brendan L Wilkinson,et al.  Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. , 2008, Journal of medicinal chemistry.

[31]  Claudiu T. Supuran,et al.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.

[32]  C. Biot,et al.  Ferrocene Conjugates of Chloroquine and other Antimalarials: the Development of Ferroquine, a New Antimalarial , 2007, ChemMedChem.

[33]  C. Supuran,et al.  Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[34]  J. Lelièvre,et al.  Trioxaquines Are New Antimalarial Agents Active on All Erythrocytic Forms, Including Gametocytes , 2007, Antimicrobial Agents and Chemotherapy.

[35]  C. Supuran,et al.  Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. , 2006, Journal of medicinal chemistry.

[36]  J. Heitman,et al.  Carbonic Anhydrase and CO2 Sensing during Cryptococcus neoformans Growth, Differentiation, and Virulence , 2005, Current Biology.

[37]  M. Tuite,et al.  Fungal Adenylyl Cyclase Integrates CO2 Sensing with cAMP Signaling and Virulence , 2005, Current Biology.

[38]  Santoshkumar N. Patil,et al.  An Easy Access to Aryl Azides from Aryl Amines under Neutral Conditions. , 2005 .

[39]  P. Newton,et al.  A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. , 2003, Molecular biology and evolution.

[40]  B. Sharp,et al.  Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.

[41]  C. Wongsrichanalai,et al.  Malaria drug-sensitivity testing: new assays, new perspectives. , 2003, Trends in parasitology.

[42]  T. Egan Structure-function relationships in chloroquine and related 4-aminoquinoline antimalarials. , 2001, Mini reviews in medicinal chemistry.

[43]  H. Ginsburg,et al.  An integrated model of chloroquine action. , 1999, Parasitology today.

[44]  M. Foley,et al.  Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. , 1998, Pharmacology & therapeutics.

[45]  J. Koella,et al.  A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. , 1993, Acta tropica.

[46]  K. Miller,et al.  Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. , 1988, The New England journal of medicine.

[47]  N. Weatherly,et al.  Plasmodium falciparum: cloning by single-erythrocyte micromanipulation and heterogeneity in vitro. , 1988, Experimental parasitology.

[48]  D Payne,et al.  Spread of chloroquine resistance in Plasmodium falciparum. , 1987, Parasitology today.

[49]  H. Ginsburg,et al.  Identification of the acidic compartment of Plasmodium falciparum‐infected human erythrocytes as the target of the antimalarial drug chloroquine. , 1984, The EMBO journal.

[50]  Shabana I. Khan,et al.  Synthesis, antimalarial activity and cytotoxicity of 4-aminoquinoline-triazine conjugates. , 2010, Bioorganic & medicinal chemistry letters.

[51]  T. Jones,et al.  Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase , 2006 .

[52]  B. K. Park,et al.  4-Aminoquinolines--past, present, and future: a chemical perspective. , 1998, Pharmacology & therapeutics.

[53]  C. Biot,et al.  Malaria Journal Assessment of Plasmodium Falciparum Resistance to Ferroquine (ssr97193) in Field Isolates and in W2 Strain under Pressure , 2022 .